Scientists have found a new way to attack breast cancer

Recently, researchers from the University of North Carolina (UNC) Center for comprehensive cancer research have found a new way to attack malignant breast cancer By working with a drug development company (http://www.chemdrug.com/), researchers hope that their laboratory findings can be translated into a new type of combination therapy for clinical use in the future The latest findings, published in cancer cell international recently, are based on the work of Dr Leslie parise, Professor of UNC lainberg comprehensive cancer research center and head of Department of Biochemistry and biophysics of medical school, who has been researching a potential new drug target for triple negative breast cancer Dr parise also co founded a company called reveris therapeutics, which is trying to develop drugs to selectively target and inhibit a protein in cells called cib1 Their latest study reveals the role of cib1, as well as a synergistic combination strategy The researchers explored what happens when breast cancer is treated with docetaxel and cib1 knockout They found that the combination therapy can selectively kill cancer cells without affecting normal cells In addition, the addition of a death signal molecule, TNF related apoptosis inducing ligand (or trail), has synergistic effect, which will lead to increased cell death, but will not kill normal cells.